Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have discovered a new compound with significantly higher anti-HIV activity and improved binding affinity to the CXCR4 receptor. This breakthrough has potential for developing new, more effective drugs against HIV-1 infections and related diseases.
Researchers found several genes in nematode worms that could be potential targets for anti-cancer therapies. By inhibiting these genes, they may reverse key traits associated with cancer cells.
Researchers have developed a method to find and kill malignant cells while sparing healthy ones using theranostic imaging. The technique relies on binding a potent drug therapy to specific proteins on tumor cell surfaces, allowing it to target cancerous cells with precision.
A new method of delivering trastuzumab via subcutaneous injection has been found to be as effective as traditional intravenous delivery, with similar pathologic complete response rates. This could simplify breast cancer treatment, saving time for patients and reducing hospital dependence.
A new clinical trial shows that drinking eight ounces of grapefruit juice daily can increase the levels of an anti-cancer drug called sirolimus in patients with incurable cancer. This combination could help patients avoid serious gastrointestinal side effects and reduce medication costs.
Researchers found a significantly lower risk of life-threatening side-effects in patients taking part in Phase I trials of new-style targeted cancer therapies. The study also identified characteristics that put patients at higher risk, such as being sicker when joining the trial.
A new 'Multi-Hit' mouse model has been developed to study interactions between gene mutations that cause cancer, revealing key findings about the role of Ras and other genes in tumour development. The research suggests that combinations of mutations can lead to cancer, making it a crucial step towards understanding treatment options.
Researchers found two opposing proteins regulating the same set of genes in prostate cancer, suggesting potential therapeutic targets. The study identified genetic markers associated with tumor relapse, which could help predict patient outcomes.
A Kaiser Permanente study found that long-term use of blood pressure medications increasing sun sensitivity is associated with a higher risk of squamous cell lip cancer in non-Hispanic whites. The risk appeared to increase with longer duration of medication use, and was not explained by cigarette smoking.
New human-derived breast cancer models retain heterogeneity, allowing researchers to test drugs more accurately. These models can help identify unique features in individual tumors, enabling targeted treatment.
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center a total of $48.2 million in new grants to support high-impact cancer research and expand access to critical prevention programs across Texas. The awards include funding for seven Multi-Investigator Research Awards and 14 projects to...
Researchers from Netherlands will investigate using DNA analysis to guide personalized cancer treatment, focusing on breast and colorectal tumors. The grant aims to improve patient outcomes by matching patients with the most effective treatments.
Researchers at Michigan State University have identified a key protein called MLK3 that drives breast cancer cell migration and invasion. By targeting this protein, they hope to develop new therapies to prevent the spread of cancer.
Scientists have developed a method to identify new uses for existing medicines, using 11 factors to pair likely drugs with diseases. The 'Train-Match-Fit-Streamline' approach could lead to repurposing of medicines like Celebrex and hookworm treatment for cancer.
A combination of anastrozole and fulvestrant extended the median survival time of women with Stage 4 hormone receptor-positive metastatic breast cancer. The treatment option showed a significant overall survival benefit, particularly exciting for patients who have not had a new treatment in over a decade.
The combination of anastrozole and fulvestrant improved overall survival and progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer. The study showed a six-month extended median survival time compared to anastrozole alone, and improved median time to disease progression.
Researchers have identified a new direction for cancer therapy by discovering a mutant form of the Chk1 gene that permanently stops cancer cell proliferation and causes cell death. This finding has the potential to reduce toxicity in cancer treatment, allowing physicians time to fix genetic errors.
A study published in the New England Journal of Medicine found that combining two drugs extended the lives of women with metastatic breast cancer by more than six months. The combination treatment produced even greater benefits among women who had not previously taken tamoxifen, significantly improving survival rates.
A new approach to treating triple negative breast cancer and clear cell renal cell carcinoma has been discovered by researchers at Mayo Clinic. The approach involves activating a potent tumor suppressor gene called sFRP1, which is silenced in these cancers. Once activated, the laboratory tumor cells stopped growing and died.
Researchers at A*STAR's Institute of Molecular and Cell Biology have devised a fast and cost-saving way to uncover genetic changes associated with cancer. By studying fruit flies, they identified new 'cooperating' genes that work together to cause aggressive cancer.
A new study found that alcohol can make certain medications up to three times more available to the body, effectively tripling their original dose. This is due to ethanol's ability to alter enzyme interactions with a wide range of medications, including those that don't dissolve well in the gastrointestinal tract.
The U.S. Food and Drug Administration has approved several precedent-setting cancer drugs that offer a glimpse into the future of personalized medicine. Companion diagnostics are being used to identify patients most likely to benefit from medication, enabling targeted treatments.
A large international study found that women who give birth at age 30 or older have a reduced risk of endometrial cancer. The risk decreases by approximately 13 percentage points for each five-year delay in last births, with the greatest reduction seen among women who give birth between ages 35 and 39.
Researchers developed a new computational method to identify novel connections between genes, drugs and scientists. The approach analyzed large datasets to create gene-gene networks, connected co-prescribed drugs and side effects, and identified collaborations.
Researchers suggest using multicellular tumor spheroid (MCTS) models to improve cancer drug discovery, as they more accurately mimic human tumors. MCTS models can help identify specific genetic mutations targeted by drugs and interact with the surrounding environment.
A new study reveals that hundreds of random mutations in leukemia cells are linked to aging, not cancer. Researchers found that even healthy individuals accumulate genetic changes over time, which can increase the risk of developing acute myeloid leukemia (AML).
A recent study found that hormone-suppressing drugs reduce oestrogen levels in obese women, but their levels remain more than double those of normal-weight women. This suggests that overweight and obese women may benefit from changes to their treatment, highlighting the need for personalized care.
A new suite of web-based tools, CellMiner, provides researchers with improved capacity to compare data from genomic information against thousands of drugs. By comparing drugs and genetic targets, researchers can identify pharmaceuticals that could be effective against different forms of cancer.
Researchers discovered an uncommon mutation of the BRAF gene in melanoma patients that responds to MEK inhibitor drugs. The BRAF L597 mutation is adjacent to the V600 mutation and was found in 4% of tumor samples, suggesting potential benefits from MEK inhibitors.
A new immunotherapy using nanolipogels (NLGs) delays tumor growth, sends tumors into remission, and increases survival rates in mice. The NLGs deliver two components: an inhibitor drug that counters TGF-β and interleukin-2 to boost the immune response.
A study published in Leukemia & Lymphoma reveals that IDH mutations drive the production of 2-hydroxyglutarate, leading to abnormal gene regulation and increased risk of relapse. Researchers believe targeting IDH mutations may hold promise for treating AML.
TGen researchers will identify genetic differences in glioblastoma patients using whole genome sequencing, with the goal of developing personalized clinical trials. The foundation's funding supports two five-year projects aimed at extending patient survival and improving treatment outcomes.
A new approach using an HIV drug has significantly reduced the incidence of graft-versus-host disease (GvHD) in bone marrow transplant patients. The treatment redirects immune cells away from vital organs, reducing the risk of GvHD without compromising the patient's ability to fight cancer.
Researchers have found a way to overcome drug resistance in childhood cancer by combining crizotinib with an mTOR inhibitor. This combination has shown promise in treating aggressive neuroblastoma tumors that are resistant to current treatments.
A Harvard researcher predicts that a multi-drug approach could make many cancers 'manageable' by targeting the KRAS gene. This strategy involves using at least two drugs to combat drug resistance, which currently limits targeted therapy's effectiveness.
Research established RNA Polymerase I (Pol I) activity as essential for cancer cell survival, and its inhibition with CX-5461 selectively activates p53 to kill tumors. The drug was shown to be 300 times more potent than non-genotoxic p53 activators.
Researchers are developing a new oral multiple sclerosis drug that targets the molecule miR-326, which stimulates the production of immune system mediators. The drug aims to inhibit miR-326 and block the production of Th17 cells, potentially offering a more convenient treatment option for patients.
Researchers developed a novel anticancer drug called G202 that targets cancer cells by activating a specific protein, sparing healthy tissues. In laboratory studies, G202 reduced human prostate tumors grown in mice by an average of 50% within 30 days, outperforming the chemotherapy drug docetaxel.
Researchers discovered a protein, IGFBP3, that helps stop cancer cell proliferation and found other proteins working together with it. This finding could lead to a therapeutic strategy to reprogram cancer cells into permanent dormancy.
The new proton therapy center will provide highly individualized treatments for cancer patients in the region, including pediatric and adult tumors. The center will be operated by UT Southwestern physicians and staff, with laboratory space for researchers and at least four treatment vaults.
A study found that women using fertility drugs had a reduced risk of breast cancer if they did not conceive a 10-plus week pregnancy, but an increased risk if they did. The study suggests that exposure to the drugs may raise risk by modifying breast tissue remodeling during pregnancy.
Researchers create high-throughput flow-through optical microscope to classify rare breast cancer cells in blood samples, boasting a throughput of 100,000 cells per second. The technology demonstrates real-time identification of rare cancer cells with a record low false-positive rate.
New research suggests that normal cells within the tumor, part of the tumor microenvironment, may supply factors that help cancer cells grow and survive despite anti-cancer drugs. The study found that hepatocyte growth factor (HGF) is linked to BRAF inhibitor drug resistance in melanoma.
A new study published in the Canadian Medical Association Journal found a potential link between the use of pioglitazone, a type of thiazolidinedione diabetes medication, and an increased risk of bladder cancer. Researchers analyzed data from over 2.6 million patients to quantify this association.
Presentations at the Genetics Society of America's Model Organism to Human Biology meeting revealed key findings on cancer genomic pathways. Researchers identified mediators of metastasis and potential drug targets in model organisms such as zebrafish, fruit flies, and roundworms.
A BUSM in vitro study discovered a potent combination therapy for breast cancer, including triple-negative and hormone-refractory cases. The treatment re-expressed imprinted tumor suppressor genes, inhibiting cancer cell growth and promoting death.
Researchers at UCSF have discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug. This discovery may lead to better treatments involving precision medicines that combine Tarceva with new drugs designed to block AXL.
The study published in Science Translational Medicine documents pre-clinical data and rationale for developing G-202 as a potential cancer therapy. G-202, combined with prodrug delivery, is effective at killing fast- and slow-growing cancers by targeting PSMA enzyme.
A new cancer drug, brentuximab vedotin (Adcetris), has dramatically improved survival rates for Hodgkin lymphoma patients who have failed other treatments. In a multi-center study, 65% of patients were alive at 24 months, and 25% had no progression of the disease.
The US government is developing medical countermeasures against nuclear threats, including acute radiation syndrome (ARS). Several companies are working on adapting existing drugs and creating new compounds to treat ARS symptoms and remove radioactive particles from the body.
Researchers at Moffitt Cancer Center tested a 2-drug combination of sirolimus and tacrolimus to prevent acute grades of graft vs. host disease after blood cell transplantation, finding it more effective than another combination in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD.
A study by the University of Kentucky Markey Cancer Center found that cancer patients experienced significant improvements in pain, stress, and nausea after one Jin Shin Jyutsu session. The study included 159 patients who reported a mean decrease of three points for stress and two points for both pain and nausea.
A systematic review of seven studies involving over 32,400 patients found that metformin reduced the risk of any type of cancer by 38% compared to those not taking the medication. The benefits were seen in colon and breast cancer, but not pancreatic cancer.
Researchers at Moffitt Cancer Center and colleagues have tested deferasirox as a treatment for myelodysplastic syndrome (MDS), a blood-related malignancy that affects the ineffective production of blood cells. Deferasirox reduced iron levels by 23% in 53% of patients, showing promising results for this type of cancer.
Researchers found that cancers with disorganized traffic systems result in lower survival rates and are more difficult to treat. A mathematical equation could help doctors determine the best course of treatment by identifying the complexity of each cancer type.
Researchers at Nationwide Children's Hospital have created a new drug to target osteosarcoma, the most common bone tumor in children, using a modified version of Celebrex. The drug, 8A, selectively inhibits the STAT3 pathway, which is crucial for tumor formation and cancer progression.
Researchers at UC San Diego have identified a new signal transduction pathway in alternative RNA splicing, which could lead to novel cancer drugs. The SRPK kinase plays a central role in regulating VEGF and controlling tumor growth.
Weill Cornell researchers devise innovative boxer-like strategy to deliver one-two punch to multiple myeloma by weakening defenses and then killing cancer cells. The approach, using two anti-cancer drugs, shows potential for treating other tumor types.
A recent study published in Gynecologic Oncology reveals that widely available cell lines are often misidentified or contaminated, leading to faulty cancer science. Researchers suggest verifying cell lines as a prerequisite for publishing, and the team is working to build a database to help identify mismatched cell lines.
Researchers uncovered surprises in genes previously thought uninvolved in breast cancer, revealing the complex drivers of this leading cause of cancer death. The study found novel fusion gene MAGI1-AKT3, which acts as an oncogene and offers new therapy targets.